Roopa Bhat, MD
Neurology · Bellevue, WANPI 1699003871
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $44,272 of the $69,525 with a category attached, or 63.7%. 33 manufacturers reported payments, led by AbbVie at 24.9% of the total. Reporting peaked in 2019 at $25,737 and has fallen 78.4% since, to $5,563 in 2025. Among neurology clinicians in WA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 385 payments — averaging $180.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$17K
- Bristol Myers Squibb$13K
- Novartis$9K
- EMD Serono, Inc.$8K
- MDD US Operations, LLC$5K
- Biohaven Pharmaceuticals, Inc.$4K
- plus $12K from 27 others
What the payments were for
- Consulting fees$7,27010%
- Speaking & faculty fees$44,27264%
- Travel & lodging$5,9609%
- Food & beverage$11,59317%
- Education$4301%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 44 | $17,316 |
| Bristol Myers Squibb | 41 | $12,989 |
| Novartis | 21 | $9,300 |
| EMD Serono, Inc. | 41 | $8,247 |
| MDD US Operations, LLC | 19 | $5,348 |
| Biohaven Pharmaceuticals, Inc. | 15 | $4,468 |
| Teva Pharmaceuticals USA, Inc. | 33 | $4,009 |
| Biohaven Pharmaceutical Holding Company Ltd. | 7 | $2,514 |
| Biogen | 15 | $769 |
| Zyla Life Sciences, Inc. | 47 | $553 |
| Lilly USA, LLC | 10 | $377 |
| Neurocrine Biosciences, Inc. | 3 | $341 |
| Pfizer | 15 | $322 |
| Sanofi | 9 | $283 |
| Harmony Biosciences LLC | 3 | $255 |
| Jazz Pharmaceuticals Inc. | 2 | $248 |
| Argenx US, Inc. | 2 | $242 |
| Impel Pharmaceuticals Inc. | 6 | $231 |
| Merz North America, Inc. | 2 | $189 |
| Novo Nordisk | 2 | $155 |
| E.r. Squibb & Sons, L.L.C. | 3 | $152 |
| AstraZeneca | 7 | $150 |
| Upsher-smith Laboratories LLC | 9 | $143 |
| Supernus Pharmaceuticals, Inc. | 14 | $137 |
| Amneal Pharmaceuticals LLC | 2 | $135 |
| TG Therapeutics, Inc. | 1 | $129 |
| Ipsen Biopharmaceuticals, Inc | 1 | $125 |
| Kyowa Kirin, Inc. | 1 | $122 |
| Acorda Therapeutics, Inc | 1 | $100 |
| Assertio Therapeutics, Inc. | 6 | $73 |
| Lundbeck LLC | 1 | $58 |
| Amgen | 1 | $26 |
| Genentech USA, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$69,525 in reported general payments places this provider in the 90th percentile of 418 neurology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 12 | $11,794 |
| Aimovig AutoinjectorErenumab-Aooe | 15 | $11,355 |
| Dalfampridine ErDalfampridine | 21 | $7,366 |
| Gabapentin | 77 | $1,045 |
| Memantine Hcl | 16 | $910 |
| Topiramate | 31 | $723 |
| AmantadineAmantadine Hcl | 15 | $627 |
| Nortriptyline Hcl | 24 | $509 |
| Propranolol Hcl | 24 | $288 |
| Tizanidine Hcl | 19 | $231 |
| Baclofen | 14 | $159 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 16 | $137 |
| Divalproex Sodium | 12 | $122 |
| Carbamazepine | 12 | $94 |
| Ondansetron OdtOndansetron | 13 | $90 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt | $322 | $11,79412 claims |
| Upsher-smith Laboratories LLCTopiramate | $143 | $72331 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 418 neurology providers in Washington.
Other neurology in Bellevue
- Mark FishelBellevue$21K
- Pavle RepovicSeattle$1.1M
- Jason AldredSpokane$1M
- Pinky AgarwalKirkland$795K
- Stacy DonlonTacoma$613K
- Nathaniel WatsonSeattle$486K
- James BowenKirkland$379K
- Christyn EdmundsonSeattle$318K
- Jessica CraddockSpokane$266K
- Pravin KhemaniSeattle$194K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.